 AIM ImmunoTech Inc NYSE:AIM said it ended the third quarter of 2022 with cash and cash equivalents of 36.7 million, down from 48.3 million at the end of December 2021, but expected to fund operations through to the end of 2023. The Ocala, Florida-based company said research and development expenses for the three months ended September 30, 2022, were 1.4 million, compared to 2 million for the same period in 2021. 